{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"49.4","value":"134"},{"groupId":"OG001","spread":"80.2","value":"185"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"description":"Plasma drug concentration at 24 hours postdose prior to the next daily dose (C24) following a single dose of avapritinib","dispersionType":"Standard Deviation","groups":[{"description":"Part 1 and Part 2: Patients received a starting dose of 300 mg QD. Patients received avapritinib in continuous 28 day cycles until discontinuation.","id":"OG000","title":"Part 1 and Part 2: Avapritinib (Formerly BLU-285) 300 mg QD"},{"description":"Part 1 and Part 2: Patients received a starting dose of 400 mg QD. Patients received avapritinib in continuous 28 day cycles until discontinuation.","id":"OG001","title":"Part 1 and Part 2: Avapritinib (Formerly BLU-285) 400 mg QD"}],"paramType":"MEAN","populationDescription":"Patients enrolled in Part 1 or Part 2 with a starting dose of 300 or 400 mg QD and available PK samples","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1","title":"Plasma Drug Concentration at 24 Hours Postdose Prior to the Next Daily Dose (C24)","type":"SECONDARY","unitOfMeasure":"ng/mL"}